医学
胰腺癌
内科学
肿瘤科
癌症
胰腺疾病
放射治疗
疾病
梅德林
癌症研究
胰腺导管腺癌
作者
Brian Matthew Wolpin,Wungki Park,Ignacio Garrido‐Laguna,Alexander I. Spira,Alexander Starodub,David Sommerhalder,Salman Rafi Punekar,Minal A. Barve,Meredith S. Pelster,Benjamin Herzberg,Nilofer Saba Azad,Joel Randolph Hecht,Sai‐Hong Ignatius Ou,Tong Lin,Sumit Kar,Lin Tao,Rashmi Vora,Aparna Hegde,Kyaw Lwin Aung,David S. Hong
标识
DOI:10.1056/nejmoa2505783
摘要
BackgroundCurrent therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate–bound mutant and wild-type RAS. MethodsIn this phase 1–2 study, we evaluated daraxonrasib in patients with advanced solid tumors with activating RAS mutations. Patients received 10 to 400 mg of daraxonrasib orally once daily; 300 mg was selected as the phase 3 dose. The primary end point was safety. Pharmacokinetics and antitumor activity were secondary end points. This report focuses on the 168 study patients with previously treated RAS-mutated PDAC. ResultsAmong the 168 patients with PDAC who received daraxonrasib at a dose of 300 mg or less, treatment-related adverse events of any grade were reported in 96%; such events of grade 3 or higher were reported in 30%. Treatment-related adverse events that occurred in at least 10% of the patients included rash, diarrhea, nausea, stomatitis or mucositis, vomiting, and fatigue. In a subgroup of 26 patients with RAS G12 mutations who were treated with second-line daraxonrasib at a dose of 300 mg, an objective response to therapy was reported in 35% (95% confidence interval [CI], 17 to 56). The median duration of response was 8.2 months (95% CI, 3.8 to not evaluable), with median values of 8.5 months for progression-free survival and 13.1 months for overall survival. Among the 38 patients with RAS G12, G13, or Q61 mutations, 29% (95% CI, 15 to 46) had an objective response. The median duration of response was 8.2 months (95% CI, 3.8 to 8.8), with median values of 8.1 months for progression-free survival and 15.6 months for overall survival. ConclusionsDaraxonrasib was associated with treatment-related adverse events of grade 3 or higher in one third of patients with previously treated RAS-mutated PDAC; antitumor activity was also reported. (Funded by Revolution Medicines; RMC-6236-001 ClinicalTrials.gov number, NCT05379985.)
科研通智能强力驱动
Strongly Powered by AbleSci AI